Increased expression cysteine-rich61 (Cyr61) in patients with thyroid carcinomas

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 22, 2011, Pages 2517-2521

  Chen, Guang ^a   Jin, Meishan ^a   Lin, Shan ^a   Wang, Peisong ^a   Liu, Jia ^a   Li, Chenyao ^a   Xu, Liyan ^b   Zhang, Wei ^c  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b SHANTOU UNIVERSITY   (China)

^c Second Hospital of Ningbo   (China)

Author keywords

CYR61; Immunohistochemistry; Real time PCR (RT PCR); Thyroid carcinomas; Transforming growth factor (TGF )

Indexed keywords

CYSTEINE RICH PROTEIN 61; MESSENGER RNA;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; UPREGULATION;

EID: 84055211911     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: 10.5897/AJPP11.708     Document Type: Article

References (16)

1. Annes JP, Munger JS, Rifkin DB (2003). Making sense of latent TGF beta activation. J. Cell. Sci., 116: 217-224.
2. Babic AM, Kireeva ML, Kolesnikova TV and Lau LF (1998). CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA. 95: 6355-6360.
3. Bartholin L, Wessner LL, Chirgwin JM, Guise TA (2007). The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett., 246: 230-236.
4. Brown RL, de Souza JA, Cohen EE (2011). Thyroid cancer: burden of illness and management of disease. J. Cancer, 2: 193-199.
5. Chen L, Klass C and Woods A (2004) Syndecan-2 regulates transforming growth factor-beta signaling. J. Biol. Chem., 279: 15715-15718.
6. Clasper S, Vekemans S, Fiore M, Plebanski M, Wordsworth P, David G and Jackson DG (1999). Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J. Biol. Chem., 274: 24113-24123.
7. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N (1998). Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell, 93: 1159-1170.
8. Dal Maso L, Bosetti C, La Vecchia C, Franceschi S (2009). Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer. Causes Control, 20: 75-86.
9. Dimartino E, Wild CP, Rotimi O, Darnton JS, Olliver RJ and Hardie LJ (2006). IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and associatedoesophageal adenocarcinoma: potential biomarkers of disease risk. Biomarkers, 11: 547-561.
10. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A (2001). CTGF and SMADs maintenance of scleroderma phenotype is independent of SMAD signaling. J. Biol. Chem., 276:10594-10596
11. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Hölzer S (2000). Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer. Jul., 89: 202-217.
12. Maeta N, Osaki M, Shomori K, Inaba A, Kidani K, Ikeguchi M and Ito H (2007). CYR61 downregulation correlates with tumor progression by promoting MMP-7 expression in human gastric carcinoma. Oncology, 73: 118-126.
13. Oshiba G, Kijima H, Himeno S, Kenmochi T, Kise Y, Tanaka H, Nishi (1999). Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas. Anticancer. Res., 19: 4375-4378.
14. Sambrook J, Russell DW (2001). Molecular cloning: A laboratory manual. 3rd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press.
15. Shaha AR (2007). TNM classification of thyroid carcinoma. World. J. Surg., 31: 879-887.
16. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, Said JW, Gornbein J and Koeffler HP(2001). Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J. Biol. Chem., 276: 14187-14194.